Mithra Files Patent Applications for its Sublingual Form Based on Estetrol Thereby Extending its IP Position to Sublingual Formulations in Contraception and Menopause Until 2036

  • Mithra files patent applications for its sublingual form based on Estetrol, an alternative formulation which could be used in menopause and contraception, including emergency contraception, offering potential protection for these indications until 2036.
  • Mithra initiates galenic formulation of its sublingual form based on Estetrol with Pharmavize, as well as a collaboration with University College London to optimize the organoleptic characteristics of this formulation.
  • Mithra hopes to obtain grant of its patents on the synthesis of Estetrol in Europ by July 2016.

Liège, Belgium, 28 April 2016 – Mithra Pharmaceuticals announces filing patent applications on sublingual forms based on Estetrol, formulations which could be could be used in menopause and contraception, including emergency contraception. The patents on these formulations could offer a protection period running until 2036.

Read the press release